Transferability of a modified embryonic stem cell test using a new endpoint for developmental neurotoxicity

Area of Science:

• Developmental Toxicology
• Stem Cell Biology
• Neuroscience

Background:

• Developmental neurotoxicity assessment is crucial for identifying harmful environmental agents.
• Existing methods for evaluating neurotoxicity have limitations in sensitivity and specificity.
• The mouse embryonic stem cell test (mESC) is a promising in vitro model for developmental toxicity.

Purpose of the Study:

• To develop and validate a novel surrogate endpoint for developmental neurotoxicity using the mESC test.
• To assess the sensitivity, specificity, and inter-laboratory transferability of the new endpoint.
• To optimize culture conditions for neuronal differentiation of mESCs.

Main Methods:

• Standardized protocol for neuronal differentiation of mouse embryonic stem cells (mESCs) across three laboratories.
• Optimization of culture media (N2B27, bFGF absence) and duration (12 days) for maximal neuronal differentiation.
• Quantification of neuronal differentiation using flow cytometry (β-III tubulin) and real-time PCR (MAP2 mRNA).

Main Results:

• Optimal mESC neuronal differentiation achieved in N2B27 medium without bFGF or ascorbic acid after 12 days.
• The new endpoint classified lead (II) acetate as weakly embryotoxic, unlike the standard EST.
• Aroclor 1254 was identified as weakly embryotoxic, while penicillin G was non-embryotoxic using the new endpoint.

Conclusions:

• A novel, sensitive, specific, and transferable surrogate endpoint for developmental neurotoxicity has been established using mESCs.
• This optimized mESC test provides a more accurate classification of embryotoxic potential for neurotoxicants.
• The developed endpoint enhances the reliability of in vitro screening for developmental neurotoxicity.